Skip to main content
. 2017 Jul 29;8(41):70317–70331. doi: 10.18632/oncotarget.19688

Figure 1. Optimization of gp33-41 vaccination strategy in WT mice.

Figure 1

(A) WT mice were primed with equimolar amounts of the pam-gp33-41 (Pam2-KMFVTAPDNLGYM) or minimal gp33-41 peptide (KAVYNFATM) and 50 μg poly-IC and 7 days later the immune responses were evaluated by tetramer staining in blood. (B) Diagrammatical representation of the vaccination protocol for panels C and D. (C, D) WT mice were primed with pam-gp33-41 BiVax and 14 days later they were boosted with pam-BiVax, pam-BiVax/IL2Cx or pam-TriVax. The percentages of Kb (B) and Db (C) tetramer+ CD8 T cells in blood after prime and boost are shown. Results are presented for individual mice (each symbol) with the mean ± SD for each group. (*p<0.05, ns: not significant).